Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ADHD Prodrug Technology
Toggle Summary KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Company's ADHD Prodrug Technology
Toggle Summary KemPharm, Inc. Appoints Todd Johnson, Ph.D. as Chief Commercial Officer
Toggle Summary KemPharm, Inc. Announces Entering Into an Exclusive Supply Agreement With Johnson Matthey Inc. for KP201
Toggle Summary KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP106 for ADHD
Toggle Summary KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD
Toggle Summary KemPharm, Inc. Expands Prodrug Pipeline with Candidate for Treatment of Pain and Closes Series B Financing